Table 3 All adverse events associated with apatinib treatment of any grade in the safety population (n = 40)
n (%) | Grades 1–2 | Grade 3 | Grade 4 | Grade 5 |
|---|---|---|---|---|
Non-haematological | ||||
Hypertension | 17 (42.5%) | 10 (25%) | 0 (0%) | 0 (0%) |
Proteinuria | 30 (75%) | 0 (0%) | – | – |
Hand–foot syndrome | 23 (57.5%) | 4 (10%) | – | – |
Mucositis | 7 (17.5%) | 2 (5%) | 0 (0%) | 0 (0%) |
Haematuria | 18 (45%) | 0 (0%) | 0 (0%) | – |
Headache | 11 (27.5%) | 0 (0%) | – | – |
Nausea | 10 (25%) | 0 (0%) | – | – |
Vomit | 8 (20%) | 0 (0%) | 0 (0%) | 0 (0%) |
Diarrhoea | 8 (20%) | 0 (0%) | 0 (0%) | 0 (0%) |
Fatigue | 23 (57.5%) | 0 (0%) | – | – |
Increased ALT | 14 (35%) | 0 (0%) | 0 (0%) | – |
Increased AST | 24 (60%) | 3 (7.5%) | 0 (0%) | – |
Increased alkaline phosphatase | 19 (47.5%) | 0 (0%) | 0 (0%) | – |
Increased L-gamma glutamyltransferase | 18 (45%) | 3 (7.5%) | 1 (2.5%) | – |
Urobilinogen | 17 (42.5%) | 0 (0%) | 0 (0%) | – |
Increased creatinine | 8 (20%) | 0 (0%) | 0 (0%) | – |
Haematological | ||||
Neutropenia | 9 (22.5%) | 1 (2.5%) | 1 (2.5%) | 0 (0%) |
Anaemia | 32 (80%) | 0 (0%) | 0 (0%) | 0 (0%) |
Thrombocytopenia | 16 (40%) | 3 (7.5%) | 0 (0%) | 0 (0%) |
